SUBSCRIBE
SUBSCRIBE

Alterome Therapeutics

NEWS
Map of NextGen Class of 2024/BioSpace
Business
NextGen Class of 2024: Top Life Sciences Startups to Watch This Year
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
January 3, 2024
 · 
20 min read
 · 
BioSpace Editorial Staff
IN THE PRESS
Press Releases
Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
October 30, 2024
 · 
2 min read
Press Releases
Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium
October 25, 2024
 · 
2 min read
Press Releases
Eric Murphy, Ph.D., Co-Founder and CEO of Alterome, Named to Goldman Sachs Top 100 Most Exceptional Entrepreneurs at 2024 Builders and Innovators Summit
October 18, 2024
 · 
3 min read
Biotech Beach
Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor
April 8, 2024
 · 
2 min read
Biotech Beach
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
April 3, 2024
 · 
4 min read
AWARDS
  • NextGen Badge - Brighspot Rework_NextGen - Class of 2024.jpg
JOBS